The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival. Issue 6 (13th May 2013)
- Record Type:
- Journal Article
- Title:
- The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival. Issue 6 (13th May 2013)
- Main Title:
- The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival
- Authors:
- Hohenauer, Tobias
Berking, Carola
Schmidt, Andreas
Haferkamp, Sebastian
Senft, Daniela
Kammerbauer, Claudia
Fraschka, Sabine
Graf, Saskia Anna
Irmler, Martin
Beckers, Johannes
Flaig, Michael
Aigner, Achim
Höbel, Sabrina
Hoffmann, Franziska
Hermeking, Heiko
Rothenfusser, Simon
Endres, Stefan
Ruzicka, Thomas
Besch, Robert - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Pigment cells and neuronal cells both are derived from the neural crest. Here, we describe the Pit‐Oct‐Unc (POU) domain transcription factor Brn3a, normally involved in neuronal development, to be frequently expressed in melanoma, but not in melanocytes and nevi. RNAi‐mediated silencing of Brn3a strongly reduced the viability of melanoma cell lines and decreased tumour growth <italic>in vivo</italic>. In melanoma cell lines, inhibition of Brn3a caused DNA double‐strand breaks as evidenced by Mre11/Rad50‐containing nuclear foci. Activated DNA damage signalling caused stabilization of the tumour suppressor p53, which resulted in cell cycle arrest and apoptosis. When Brn3a was ectopically expressed in primary melanocytes and fibroblasts, anchorage‐independent growth was increased. In tumourigenic melanocytes and fibroblasts, Brn3a accelerated tumour growth <italic>in vivo</italic>. Furthermore, Brn3a cooperated with proliferation pathways such as oncogenic BRAF, by reducing oncogene‐induced senescence in non‐malignant melanocytes. Together, these results identify Brn3a as a new factor in melanoma that is essential for melanoma cell survival and that promotes melanocytic transformation and tumourigenesis.</p> </abstract>
- Is Part Of:
- EMBO molecular medicine. Volume 5:Issue 6(2013:Jun.)
- Journal:
- EMBO molecular medicine
- Issue:
- Volume 5:Issue 6(2013:Jun.)
- Issue Display:
- Volume 5, Issue 6 (2013)
- Year:
- 2013
- Volume:
- 5
- Issue:
- 6
- Issue Sort Value:
- 2013-0005-0006-0000
- Page Start:
- 919
- Page End:
- 934
- Publication Date:
- 2013-05-13
- Subjects:
- Molecular biology -- Periodicals
Medical genetics -- Periodicals
Pathology, Molecular -- Periodicals
616.04205 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1757-4684 ↗
http://www3.interscience.wiley.com/journal/120756871/home ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/emmm.201201862 ↗
- Languages:
- English
- ISSNs:
- 1757-4676
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3155.xml